What are the guidelines for prostate cancer contouring in radiation therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prostate Cancer Contouring Guidelines for Radiation Therapy

Essential Imaging and Planning Requirements

Clinicians must utilize CT-based treatment planning with MRI fusion for optimal prostate contouring, as this combination significantly reduces inter-observer variation and improves target delineation accuracy compared to CT alone. 1, 2

Imaging Modalities and Simulation

  • CT simulation is mandatory for treatment planning, providing the electron density data necessary for dose calculation and serving as the primary dataset for contouring 3

  • MRI fusion to CT is strongly recommended using intraprostatic fiducial markers for co-registration rather than bony landmarks, as this technique reduces inter-observer contouring variation (mean SEV/SCV ratio of 1.37 for MRI vs 1.58 for CT, p=0.036) 2, 4

  • Multiparametric MRI (combining T2-weighted imaging, diffusion-weighted imaging, and dynamic contrast-enhanced imaging) provides superior visualization of the prostate capsule, extraprostatic extension, and seminal vesicle invasion compared to CT 1, 4

Target Volume Delineation

The clinical target volume (CTV) should include the entire prostate gland with precise attention to common contouring errors at the apex, mid-gland, and base. 1, 5

Specific Anatomic Considerations by Region:

At the Prostatic Apex:

  • The most common error is overestimation due to inclusion of the genitourinary diaphragm, rectum, and anterior fascia 5
  • The posterior apical border should be defined 3.6 mm more posteriorly on MRI than typically contoured on CT to avoid geographic miss 2
  • Careful identification of the levator ani muscles is essential to avoid including these structures 1

At the Mid-Gland:

  • Overestimation commonly occurs due to inclusion of anterior and lateral fasciae 5
  • The prostate should maintain a globular form when viewed in lateral projection; deviation from this suggests contouring error 5

At the Prostatic Base:

  • Anterior overestimation occurs from inclusion of bladder wall and anterior fascia 5
  • Transition zone hypertrophy and bladder neck variability contribute to both over- and underestimation at the superior base 5
  • Variable prostate-to-seminal vesicle relationships require careful attention, particularly with prostate hypertrophy 5

Seminal Vesicle Contouring

  • For low-risk disease: Seminal vesicles typically do not require inclusion in the CTV 3

  • For intermediate-risk disease: Consider including the proximal 1-2 cm of seminal vesicles, particularly with Gleason 4+3 or other adverse features 6

  • For high-risk disease: Include seminal vesicles in the treatment volume, recognizing that seminal vesicle volumes can vary by up to 100% during treatment 7

Planning Target Volume (PTV) Margins

Dose escalation to 78-79 Gy using 3-D conformal radiation technique requires margins of no more than 10 mm at the prostatic-rectal interface. 3

  • Image-guided radiation therapy (IGRT) is mandatory for doses ≥78 Gy to enable margin reduction and improve treatment accuracy 3

  • Acceptable IGRT techniques include: daily cone-beam CT, ultrasound localization, implanted fiducial markers with orthogonal imaging, or electromagnetic tracking 3

  • Prostate motion during treatment averages <1 mm left-right, but ranges 0 to ±1 cm in anterior-posterior and superior-inferior directions, necessitating daily localization 7

Organs at Risk (OAR) Delineation

The rectum must be carefully contoured to optimize the therapeutic ratio, as it is the primary dose-limiting structure. 1

  • Rectal contouring should extend from the anorectal junction to the rectosigmoid flexure 1

  • Bladder contouring should include the entire organ, recognizing that bladder volumes vary by ±30% during treatment 7

  • Consider rectal spacer placement during simulation to increase the distance between prostate and rectum, particularly for dose-escalated treatments 3

Technical Planning Requirements

Modern radiation therapy must employ intensity-modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) as the minimum standard. 3

  • 3D conformal RT using at least four fields is the minimum acceptable technique, though IMRT/VMAT is now considered state-of-the-art and required 3

  • High-energy photon beams (≥6 MV) should be used 3

  • Multileaf collimator technology is essential for conformal dose delivery 3

Quality Assurance

Post-treatment dosimetry verification is essential to document adequate target coverage. 3

  • For brachytherapy, an excellent implant is defined as ≥90% of prostate volume receiving ≥100% of prescription dose 3

  • For EBRT, verify that dose constraints for rectum and bladder are met according to published normal tissue dose objectives 3

Common Pitfalls to Avoid

  • Do not rely on bony anatomy alone for CT-MRI fusion; use intraprostatic fiducial markers for superior accuracy 2

  • Inspect lateral view of contours to detect deviation from expected globular prostate form, which indicates likely contouring error 5

  • Recognize that bladder and rectal filling significantly affects prostate position; implement consistent bladder/rectum filling protocols during simulation and treatment 7

  • Account for organ motion by using daily IGRT rather than relying solely on initial setup, as prostate position varies by up to 1 cm during treatment course 7

  • Avoid including genitourinary diaphragm at the apex, which is the most common source of overestimation 5

References

Research

ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2018

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

MR imaging of prostate cancer in radiation oncology: what radiologists need to know.

Radiographics : a review publication of the Radiological Society of North America, Inc, 2013

Guideline

Management of Intermediate-Risk Prostate Cancer

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.